On June 25, Innovent Biologics fell 3.01% in regular trading, trading at 75.35 HKD/share, with turnover of 175 million HKD.

On the news front, the company held its annual general meeting on June 24, where all seven ordinary resolutions passed but encountered unusually high opposition. Notably, the resolution to expand general mandate for share issuance by adding back buyback shares received 48.48% opposition votes. The resolution granting directors general authority to allot and issue additional shares faced 36.68% opposition, while the auditor reappointment resolution saw 22.78% dissent. The high proportion of opposing votes signals significant shareholder discontent with capital management decisions.

Within the Biotechnology sector, the overall sector is under pressure. Among individual stocks, AKESO down 4.0%, REMEGEN down 4.06%, CARSGEN down 7.98%, 3SBIO down 2.13%, BEIGENE down 0.91%, creating broad-based downward momentum that amplified selling pressure on Innovent Biologics.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)